A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC).
Oral Presentation; [Abstract number: 5502; Location: S406 (Vista Room)]
Time: Sunday, June 1, 5:30 p.m. 5:45 p.m.
Authors: B. M. Slomovitz, K. H. Lu, T. Johnston, M. Munsell, L. M. Ramondetta, R. R. Broaddus, R. L. Coleman, C. Walker, D. M. Gershenson, T. W. Burke, J. Wolf
Dr. Brian Slomovitz will present results from a Phase II clinical trial (during an oral presentation) showing that the orally administered experimental drug RAD001, a mammalian target of rapamycin (mTOR) inhibitor, is beneficial in patients with recurrent endometrial cancer. The drug blocks the activity of the mTOR protein within the cytoplasm of cancer cells, responsible for cancer cell proliferation and growth. The physician-scientists found that the drug slowed cancer progression in 44 percent of subjects in the study. The study was conducted in collaboration with the MD Anderson Cancer Center.
Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. [Abstract number: 7557; Poster number 34G]
Time: Sunday, June 1, 2:00 p.m. 6:00 p.m.
Authors: N. Altorki, M. Guarino, P. Lee, H. I. Pass, E. Filip, T. Bauer, D. Roychowdhury, T. Zaks, L. Ottesen, D. Yankelevitz
Dr. Nasser Altorki will present final data from a Phase II clinical trial showing that a drug that stops bl
|Contact: Andrew Klein|
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College